Follow

Herantis Pharma Oyj

Nasdaq First North GM Stockholm (Sweden)
Nasdaq First North GM Helsinki (Finland)

Herantis Pharma is a pharmaceutical drug development company. It focused on developing regenerative medicine for unmet clinical needs. The products of the group are CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, CDNF for Amyotrophic lateral sclerosis and CDNF for other neurodegenerative diseases.
Go to market

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Media
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
HRTIS
FI4000087861
Nasdaq First North GM Helsinki
Finland (FI)
Details of share in Herantis Pharma Oyj with ticker HRTIS
Status
Active
Amount of instruments
9 757 068
Currency
EUR
Segment
Regular
First trading date
11 Jun 2014
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Directed issue
Sign in to buy
Rights issue
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
HRNTS
FI4000087861
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Herantis Pharma Oyj with ticker HRNTS
Status
Active
Amount of instruments
9 757 068
Currency
SEK
First trading date
16 Dec 2019
Rights issue
Sign in to buy
People
Craig Cook
CEO
Timo Ilari Veromaa
Chairman of the board
James Neil Phillips
Board member
Frans Gustaf Wuite
Board member
Timo Ilari Veromaa
Board member
Aki Prihti
Board member
Mats Thoren
Board member
Hilde Furberg
Board member
Company Details
Sector
HEALTH CARE

Address
Bertel Jungin Aukio 1
Zip code
026 00
City/district
Espoo
Country
Finland (FI)
Registration number
2198665-7
LEI code
743700W4CQVYAT3WKK38
First trade date
11 Jun 2014
Registration date
26 May 2008
Short name
Herantis

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More